Tikvah Management’s aTyr Pharma ATYR Stock Holding History

Tikvah Management’s Portfolio ATYR Stock Details ATYR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-460,833	Closed	-$361K	–	22
2025 Q4	$361K	Hold	460,833	–	–	0.1%	23
2025 Q3	$332K	Sell	460,833 -2,000,000	-81%	-$9.06M	0.1%	23
2025 Q2	$12.5M	Hold	2,460,833	–	–	4.02%	7
2025 Q1	$7.43M	Hold	2,460,833	–	–	2.53%	13
2024 Q4	$8.91M	Hold	2,460,833	–	–	2.43%	16
2024 Q3	$4.33M	Hold	2,460,833	–	–	1.34%	17
2024 Q2	$3.84M	Hold	2,460,833	–	–	1.25%	17
2024 Q1	$4.8M	Hold	2,460,833	–	–	1.5%	16
2023 Q4	$3.47M	Hold	2,460,833	–	–	1.19%	16
2023 Q3	$3.89M	Hold	2,460,833	–	–	1.39%	17
2023 Q2	$5.32M	Hold	2,460,833	–	–	1.81%	13
2023 Q1	$5.17M	Buy	2,460,833 +1,110,000	+82%	+$2.43M	2.12%	13
2022 Q4	$2.96M	Hold	1,350,833	–	–	1.41%	14
2022 Q3	$4.05M	Hold	1,350,833	–	–	1.87%	12
2022 Q2	$3.82M	Hold	1,350,833	–	–	1.65%	16
2022 Q1	$7.23M	Buy	1,350,833 +125,000	+10%	+$708K	2.31%	12
2021 Q4	$9.16M	Buy	+1,225,833	New	+$10.2M	2.55%	12

Other funds holding ATYR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Tikvah Management's ATYR Position: Q1 2026 in Review

Tikvah Management sold out of aTyr Pharma (ATYR) in Q1 2026, closing a stake of 460,833 shares — an estimated $361K sold.

Tikvah Management first reported a position in ATYR in Q4 2021 and held it in 17 quarters. The position peaked at $12.5M in Q2 2025. 111 funds tracked by Wall St. Rank hold ATYR as of Q1 2026.

Tikvah Management reported no remaining aTyr Pharma position as of Q1 2026 after selling out during the quarter.
Tikvah Management sold 460,833 aTyr Pharma shares in Q1 2026, an estimated $361K.
Tikvah Management first reported a position in aTyr Pharma in Q4 2021 and held it in 17 quarters.
Tikvah Management's aTyr Pharma position peaked at $12.5M in Q2 2025.
111 funds tracked by Wall St. Rank held aTyr Pharma as of Q1 2026.

Based on Tikvah Management's 13F filing for Q1 2026, filed 14 May 2026.